midazolam has been researched along with cabazitaxel in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloemendal, HJ; Janssen, A; Mathijssen, RHJ; Ter Heine, R; van der Vlist, A; Verkleij, CPM | 1 |
1 other study(ies) available for midazolam and cabazitaxel
| Article | Year |
|---|---|
Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
Topics: Aged; Anti-Anxiety Agents; Antineoplastic Agents; Body Surface Area; Carcinoma; Cytochrome P-450 CYP3A; Humans; Male; Midazolam; Phenotype; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |